RxDoctor Payments Data

Michael Babinski, NP

Adult Health · Highland, ILNPI 1699362020

Payments from drug & device makers

$2,240in general payments, 2019–2025

Across 101 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$306
  • AbbVie$214
  • Lilly USA, LLC$155
  • Phathom Pharmaceuticals, Inc.$148
  • Novo Nordisk$142
  • Medtronic$138
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$2,22399%
  • Other$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,240 in reported general payments places this provider in the 85th percentile of 553 adult health providers in Illinois.

See all adult health providers in Illinois

Medicare billing

Part B allowed, 2024
$14,941
Medicare patients
121
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$21,025
MounjaroTirzepatide13$12,743
EliquisApixaban12$10,461
FarxigaDapagliflozin Propanediol11$9,057
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,550
Gabapentin41$1,001
Omeprazole34$729
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$709
Atorvastatin Calcium56$673
Albuterol Sulfate HfaAlbuterol Sulfate34$603
Tamsulosin Hcl18$596
Metoprolol Succinate29$581
Pregabalin15$579
Alendronate Sodium27$576
Famotidine33$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$142$21,02519 claims
AstraZenecaFarxiga, Breztri Aerosphere$306$16,60723 claims
Lilly USA, LLCMounjaro$155$12,74313 claims
PfizerEliquis$107$10,46112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 553 adult health providers in Illinois.

Other adult health in Highland

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →